Empagliflozin-Induced Euglycemic Diabetic
Ketoacidosis After Esophagectomy

Max Zhukovsky MD; Shreyajit R Kumar MD; Jyun you Liou MD; Christopher Tam MD

Case Report

Empagliflozin-Induced Euglycemic Diabetic Ketoacidosis After Esophagectomy

Max Zhukovsky MD, Shreyajit R Kumar MD*, Jyun you Liou MD and Christopher Tam MD

Department of Anesthesiology, Weill Cornell Medicine, USA

Corresponding Author

Received Date: October 28, 2021; Published Date:November 29, 2021

Abstract

Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are widely prescribed to patients with type 2 diabetes mellitus (T2DM), and were FDA approved in 2013. SGLT2i treatment has become commonplace. The American Diabetes Association (ADA) recommends their use as a second-line agent after metformin in patients with T2DM, or as a first-line agent in those who cannot tolerate metformin [1]. SGLT2i act by disrupting renal glucose resorption in the proximal tubule, increasing urinary glucose excretion, which lowers plasma glucose levels and HbA1c. Unlike other antihyperglycemic agents, SGLT2i do not interfere with endogenous glucose production nor stimulate insulin release. For this reason, this class has an attractive safety profile with substantially decreased risk of major hypoglycemic events [2].

Article Details

Citation

Max Zhukovsky MD, Shreyajit R Kumar MD, Jyun you Liou MD, Christopher Tam MD. Empagliflozin-Induced Euglycemic Diabetic Ketoacidosis After Esophagectomy. Anaest & Sur Open Access J. 3(1): 2021. ASOAJ.MS.ID.000552.